News

The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

How one resident found a free and accessible way to cope with her arachnophobia.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

The fact that celiac disease has effects on the brain is recognized but not completely understood.

Why are older patients turning to cannabis for symptom relief?

At least 300 to 400 physicians a year die by suicide in the United States. Learn more about the latest statistics.

The FDA has authorized key modifications to the administration protocol for injectable long-acting opioid use disorder treatment buprenorphine.

Learn more about how to appropriately diagnose and categorize a spectrum of posttraumatic stress responses in children and adolescents.

“Give me your tired, your poor, your huddled masses yearning to breathe free…”

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

How has the field of child and adolescent psychiatry matured over the last 3 decades? Our Special Report Chair, Peter S. Jensen, MD, elaborates.

How can you provide comprehensive care in underserved environments, particularly for individuals with complex mental health needs? Amitha Dhingra, MD, weighs in.

What can psychiatry learn from a podcast about grief?

"Make America Healthy Again” has taken a jab at psychiatry.

Antipsychiatry’s animus toward psychiatric medication has both ancient and modern parallels.

Frontal lobe syndrome can present with a range of perseverative, disinhibited, overactive behaviors that do not meet traditional dementia/neurocognitive disorder criteria. Learn more here.

Massive federal layoffs: how will this impact mental health?

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

Who is the ‘bad guy’ of health care? Insurance? Clinicians? Or something else?

Honoring Lisa Hunter Romanelli, PhD, the Elevate Prize will help scale REACH's work in addressing the children’s mental health crisis.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

In the psychiatric care continuum, insurance companies encourage a broader conversation about what constitutes best treatment practices.

Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis.

Judith S. Beck, PhD, and Janeé M. Steele, PhD, engage in a conversation about how clinicians from all backgrounds can address issues of race in session and also empower Black patients with a sense of personal pride in their identities.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA.